Our study demonstrates that the antiproliferative activity of TKIs against primary CML CD34+ cells is likely mediated by the reactivation of FOXO1, 3a, and 4. The gene discussed is CD34; the disease is chronic myelogenous leukemia, BCR-ABL1 positive.